Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RCT2100 inhaled dose-escalation study in adults with cystic fibrosis
NL-OMON59479Phase 2Completed
- Sponsor
- ReCode Therapeutics
- Start
- Aug 2024
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of RCT2100 in cystic fibrosis (CF) (2 arms), sponsored by ReCode Therapeutics. Primary endpoint: Safety and tolerability. Started Aug 2024; status: completed.
02
Drugs
RCT2100
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON59479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59479.